File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models

TitlePreclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models
Authors
Issue Date2014
Citation
Cancer Letters, 2014, v. 343 n. 1, p. 24-32 How to Cite?
AbstractThe dual PI3K-mTOR inhibitor BEZ235 was evaluated in preclinical models of nasopharyngeal carcinoma (NPC). The IC50 value of BEZ235 for growth was in the nanomolar range in vitro, induce G1 cycle arrest and apoptosis, and inhibited AKT and mTOR signaling in most NPC cell lines. No synergistic effect was observed when BEZ235 was combined with chemotherapy. BEZ235 increased MAPK activation in vitro but not in vivo. A daily schedule was more effective than a weekly schedule on tumor growth and inhibition of downstream mTOR signaling in vivo. The activity of BEZ235 maybe independent of the PIK3CA amplification and mutation status. © 2013 Elsevier Ireland Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/194454
ISSN
2015 Impact Factor: 5.992
2015 SCImago Journal Rankings: 2.331
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMa, BBY-
dc.contributor.authorLui, VWY-
dc.contributor.authorHui, CWC-
dc.contributor.authorLau, CPY-
dc.contributor.authorWong, CH-
dc.contributor.authorHui, EP-
dc.contributor.authorNg, MHL-
dc.contributor.authorCheng, SH-
dc.contributor.authorTsao, SW-
dc.contributor.authorTsang, C-M-
dc.contributor.authorCheung, CSF-
dc.contributor.authorHo, K-
dc.contributor.authorChan, ATC-
dc.date.accessioned2014-01-30T03:32:36Z-
dc.date.available2014-01-30T03:32:36Z-
dc.date.issued2014-
dc.identifier.citationCancer Letters, 2014, v. 343 n. 1, p. 24-32-
dc.identifier.issn0304-3835-
dc.identifier.urihttp://hdl.handle.net/10722/194454-
dc.description.abstractThe dual PI3K-mTOR inhibitor BEZ235 was evaluated in preclinical models of nasopharyngeal carcinoma (NPC). The IC50 value of BEZ235 for growth was in the nanomolar range in vitro, induce G1 cycle arrest and apoptosis, and inhibited AKT and mTOR signaling in most NPC cell lines. No synergistic effect was observed when BEZ235 was combined with chemotherapy. BEZ235 increased MAPK activation in vitro but not in vivo. A daily schedule was more effective than a weekly schedule on tumor growth and inhibition of downstream mTOR signaling in vivo. The activity of BEZ235 maybe independent of the PIK3CA amplification and mutation status. © 2013 Elsevier Ireland Ltd.-
dc.languageeng-
dc.relation.ispartofCancer Letters-
dc.titlePreclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.canlet.2013.09.007-
dc.identifier.pmid24041865-
dc.identifier.scopuseid_2-s2.0-84890860747-
dc.identifier.hkuros246480-
dc.identifier.volume343-
dc.identifier.issue1-
dc.identifier.spage24-
dc.identifier.epage32-
dc.identifier.isiWOS:000331163500004-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats